Cencora stock: Cencora agrees to acquire oncology network. What it means for Cencora stock

Published on 10/21/2026 at 16:47 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

The network spans 21 states and more than 350 providers. Cencora stock costs EUR 303.95 on October 21, 2026, down 0.60 percent versus Tradegate close.

Acquisition and price at a glance

Cencora agreed to acquire American Oncology Network for USD 2.40 billion on October 21, 2026.
The transaction includes approximately USD 1.70 billion in expected cash outlay and could add more than 350 providers across 21 states.
Cencora stock costs EUR 303.95 at Lang & Schwarz on October 21, 2026 at 4:36 p.m. CEST, 0.60 percent below the Tradegate close of October 20, 2026.
Cencora expects to report fourth-quarter fiscal 2026 results on November 4, 2026.

Luftbild eines modernen Pharma-Lagerzentrums mit Lieferfahrzeugen und Verladedocks — Cencora Inc. betreibt US15135B1017 ein großes Pharmadistributionszentrum mit Lastwagen Gabelstaplern und täglicher Medikamentenlogistik, Illustration mit AI erstellt.

Cencora Inc. (ISIN US03073E1055) agreed on October 21, 2026 to acquire American Oncology Network in a transaction valued at USD 2.40 billion, according to Business Wire. The agreement covers a physician-led network with more than 350 oncology providers across 21 states. Cencora stock was trading at EUR 303.95 at Lang & Schwarz on October 21, 2026 at 4:36 p.m. CEST, 0.60 percent below the Tradegate close of October 20, 2026 (EUR 305.80).

What does USD 2.40 billion mean?

Cencora already owns approximately 4 percent of American Oncology Network and plans to acquire the remaining equity interests. The transaction includes USD 2.30 billion at closing and contingent value rights of up to USD 100.00 million. Assuming a 25 percent equity rollover by certain shareholders, Cencora expects to pay approximately USD 1.70 billion to raise its ownership to 75 percent, according to Business Wire. Management expects the acquisition to be accretive to adjusted diluted earnings per share in the second year after closing.

Stock position has room below high

The NYSE quote stood at USD 340.52 on October 21, 2026 at 10:45 a.m. ET. Cencora's 52-week range was USD 244.82 to USD 377.54, placing the latest U.S. price 9.81 percent below the high and 39.09 percent above the low. Trading volume was 201,664 shares at that time. The market capitalization was USD 65.0 billion.

Valuation and November results

Cencora's trailing price-to-earnings ratio was 25.28 on October 21, 2026. The company said the acquisition is subject to regulatory clearances, shareholder approvals and other customary closing conditions. Its adjusted diluted earnings-per-share expectation for fiscal 2026 is now at least USD 17.90, the high end of its previous USD 17.75 to USD 17.95 range, according to Business Wire.

Cencora plans to publish fourth-quarter fiscal 2026 results before the New York Stock Exchange opens on November 4, 2026, with the conference call scheduled for 8:30 a.m. ET, according to Cencora.

Price remains below the yearly high

The acquisition adds a new oncology platform to Cencora's existing specialty-services strategy, while the USD 2.40 billion enterprise value gives investors a concrete measure for the expansion. The current euro quotation remains below the Tradegate close of October 20, 2026, even as the U.S. price sits well above its 52-week low. The further course of trading is shown by the continuously updated real-time quote of Cencora stock.